<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938297</url>
  </required_header>
  <id_info>
    <org_study_id>ZR2 for PCNSL/SCNSL</org_study_id>
    <nct_id>NCT04938297</nct_id>
  </id_info>
  <brief_title>Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma</brief_title>
  <official_title>Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the synergistic effects of rituximab, zanubrutinib, and lenalidomide and severe&#xD;
      complications caused by current standard chemotherapy regimens in Patients for primary or&#xD;
      secondary CNS lymphoma, we intend to conduct a prospective clinical study to evaluate the&#xD;
      efficacy and toxicity of Rituximab, Zanubrutinib in combination with Lenalidomide. Besides,&#xD;
      the efficacy of Zanubrutinib or Lenalidomide in maintenance was also compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>at the end of 8 cycles of induction therapy (each cycle is 28 days)</time_frame>
    <description>To evaluate the overall response rate of ZR2 in the treatment of CNS Lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>at the end of 4 cycles of induction therapy (each cycle is 28 days) and 1 year of maintenance therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rate</measure>
    <time_frame>at the end of 8 cycles of induction therapy (each cycle is 28 days), 1 year and 2 year of maintenance therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）rate</measure>
    <time_frame>at the end of 8 cycles of induction therapy (each cycle is 28 days), 1 year and 2 year of maintenance therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>at the end of 8 cycles of induction therapy (each cycle is 28 days), 1 year and 2 year of maintenance therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>Primary CNS Lymphoma，age&gt;65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent/refractory primary CNS lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Lenalidomide, Zanubrutinib</intervention_name>
    <description>Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.</description>
    <arm_group_label>Primary CNS Lymphoma，age&gt;65</arm_group_label>
    <arm_group_label>Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion</arm_group_label>
    <arm_group_label>Recurrent/refractory primary CNS lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Zanubrutinib</intervention_name>
    <description>Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression</description>
    <arm_group_label>Primary CNS Lymphoma，age&gt;65</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression</description>
    <arm_group_label>Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion</arm_group_label>
    <arm_group_label>Recurrent/refractory primary CNS lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  voluntarily participate in clinical research, fully understand the study and sign the&#xD;
             informed consent form (ICF), willing to follow and be able to complete all research&#xD;
             steps&#xD;
&#xD;
          -  histologically confirmed diffuse large B-cell lymphoma (DLBCL), all subjects must&#xD;
             provide enough archived or fresh tumor tissue samples for immunhistochemistry (IHC)&#xD;
             and gene expression profile (GEP) evaluation&#xD;
&#xD;
          -  For untreated primary CNS lymphoma, patients should be with an age of 65 years or&#xD;
             older, intolerable to first-line treatment&#xD;
&#xD;
          -  Recurrent or refractory disease was defined as: 1) recurrence of disease after&#xD;
             complete remission (CR), or 2) partial remission (PR), stable disease (SD), or&#xD;
             progressive disease (PD) at the time of completion of treatment before inclusion&#xD;
&#xD;
          -  Recurrent / refractory diffuse large B-cell lymphoma with CNS involvement confirmed by&#xD;
             histopathology or imaging&#xD;
&#xD;
          -  Age ≥ 18 years, ECoG score ≤ 2, expected survival time is more than 3 months&#xD;
&#xD;
          -  Patients with solid lesions must obtain clear evidence of disease progression through&#xD;
             imaging examination (head MRI or head CT) 21 days before enrollment. For patients with&#xD;
             leptomeningeal involvement only, CSF cytology examination must confirm lymphoma cells&#xD;
             and / or imaging findings consistent with CSF disease 21 days before enrollment (at&#xD;
             the discretion of the investigator)&#xD;
&#xD;
          -  With sufficient organ and bone marrow function , and no severe hematopoietic, heart,&#xD;
             lung, liver, kidney, thyroid dysfunction and immune deficiency&#xD;
&#xD;
          -  at least 100 days after transplantation for recurrent patients after ATST&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologically transformed large cell lymphoma&#xD;
&#xD;
          -  History of previous transplantation of allogeneic stem cells&#xD;
&#xD;
          -  Received BTKi or Lenalidomide&#xD;
&#xD;
          -  Received corticosteroid within 7 days for antitumor treatment&#xD;
&#xD;
          -  Received chemotherapy, radiotherapy, monoclonal antibody, experimental treatment, or&#xD;
             traditional Chinese Medicine within 4 weeks&#xD;
&#xD;
          -  Received major surgery within 4 weeks&#xD;
&#xD;
          -  Active malignant diseases within 2 years before entering the study&#xD;
&#xD;
          -  Clinically significant cardiovascular diseases&#xD;
&#xD;
          -  History of severe bleeding diseases&#xD;
&#xD;
          -  history of stroke or intracranial hemorrhage within 6 months before the first&#xD;
             administration&#xD;
&#xD;
          -  Unable to swallow capsules or have diseases that significantly affect gastrointestinal&#xD;
             function&#xD;
&#xD;
          -  Uncontrolled systemic infection requiring parenteral anti infective therapy&#xD;
&#xD;
          -  HIV infection or indicate active hepatitis B or C virus infection&#xD;
&#xD;
          -  Drug allergies or metabolic disorders&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any life-threatening diseases, medical conditions or organ system dysfunction that the&#xD;
             researchers believe may affect the safety of the subjects or lead to research risks&#xD;
&#xD;
          -  Required to continuously treated with potent and moderate CYP3A inhibitors or inducers&#xD;
&#xD;
          -  History of deep venous thrombosis (DVT) or pulmonary embolism (PE) in the past 12&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keshu Zhou, Dr.</last_name>
    <phone>13674902391</phone>
    <email>drzhouks77@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshu Zhou</last_name>
      <phone>13674902391</phone>
      <email>drzhouks77@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>zhoukeshu</investigator_full_name>
    <investigator_title>Associate Director of Hematology</investigator_title>
  </responsible_party>
  <keyword>Primary CNS Lymphoma</keyword>
  <keyword>Zanubrutinib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Secondary CNS Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

